Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.
Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.
Part 3: Scrip spoke with companies working on cell and gene therapies and novel approaches to neurological diseases during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
A worst-case Brexit scenario – a disorderly one – has become more likely, making an already white-knuckled life sciences industry step up its preparations.
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.
How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.
City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.
The majority of pharmaceutical companies in the UK work closely with the NHS and In Vivo spoke to one of them – Janssen – to see how successful industry, health care providers and payers have been in breaking out of their silos and collaborating.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.